vs
Side-by-side financial comparison of CECO ENVIRONMENTAL CORP (CECO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
CECO ENVIRONMENTAL CORP is the larger business by last-quarter revenue ($205.9M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). On growth, CECO ENVIRONMENTAL CORP posted the faster year-over-year revenue change (16.5% vs 5.0%). Over the past eight quarters, CECO ENVIRONMENTAL CORP's revenue compounded faster (22.4% CAGR vs -0.2%).
CECO Environmental Corp. is an American industrial technology company founded in 1966 and headquartered in Dallas, Texas. It is publicly traded on the Nasdaq Stock Market under the ticker symbol CECO. The company provides air pollution control technology, products, and services for industrial markets, including manufacturing, chemical processing, energy, and refining.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
CECO vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.9M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | 31.0% | — |
| Operating Margin | 0.9% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 16.5% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.98 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $205.9M | $177.4M | ||
| Q4 25 | $214.7M | $196.9M | ||
| Q3 25 | $197.6M | $179.5M | ||
| Q2 25 | $185.4M | $181.1M | ||
| Q1 25 | $176.7M | $168.9M | ||
| Q4 24 | $158.6M | $187.3M | ||
| Q3 24 | $135.5M | $168.6M | ||
| Q2 24 | $137.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $3.1M | — | ||
| Q3 25 | $1.5M | $5.4M | ||
| Q2 25 | $9.5M | $-4.8M | ||
| Q1 25 | $36.0M | $4.8M | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | $2.1M | $-143.5M | ||
| Q2 24 | $4.5M | $18.9M |
| Q1 26 | 31.0% | — | ||
| Q4 25 | 35.1% | 79.5% | ||
| Q3 25 | 32.7% | 80.9% | ||
| Q2 25 | 36.2% | 77.4% | ||
| Q1 25 | 35.2% | 79.7% | ||
| Q4 24 | 35.8% | 78.7% | ||
| Q3 24 | 33.4% | 76.9% | ||
| Q2 24 | 35.7% | 75.1% |
| Q1 26 | 0.9% | 3.9% | ||
| Q4 25 | 7.7% | 1.2% | ||
| Q3 25 | 4.8% | 3.5% | ||
| Q2 25 | 9.7% | 4.7% | ||
| Q1 25 | 35.0% | 1.2% | ||
| Q4 24 | 7.1% | 13.2% | ||
| Q3 24 | 5.3% | -82.8% | ||
| Q2 24 | 6.7% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.8% | 3.0% | ||
| Q2 25 | 5.1% | -2.7% | ||
| Q1 25 | 20.4% | 2.8% | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 1.5% | -85.1% | ||
| Q2 24 | 3.3% | 10.6% |
| Q1 26 | $0.98 | $0.07 | ||
| Q4 25 | $0.09 | $0.05 | ||
| Q3 25 | $0.04 | $0.12 | ||
| Q2 25 | $0.26 | $-0.11 | ||
| Q1 25 | $0.98 | $0.10 | ||
| Q4 24 | $0.14 | $0.38 | ||
| Q3 24 | $0.06 | $-3.11 | ||
| Q2 24 | $0.12 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.4M | $144.3M |
| Total DebtLower is stronger | $5.3M | — |
| Stockholders' EquityBook value | $317.2M | $653.9M |
| Total Assets | $1.0B | $1.2B |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $45.4M | $144.3M | ||
| Q4 25 | $33.1M | $238.4M | ||
| Q3 25 | $32.8M | $246.3M | ||
| Q2 25 | $36.8M | $445.9M | ||
| Q1 25 | $146.5M | $493.6M | ||
| Q4 24 | $37.8M | $484.6M | ||
| Q3 24 | $38.7M | $453.8M | ||
| Q2 24 | $36.5M | $404.2M |
| Q1 26 | $5.3M | — | ||
| Q4 25 | $212.4M | $372.2M | ||
| Q3 25 | $220.9M | $376.7M | ||
| Q2 25 | $238.7M | $580.5M | ||
| Q1 25 | $339.7M | $583.4M | ||
| Q4 24 | $218.9M | $585.3M | ||
| Q3 24 | $133.4M | — | ||
| Q2 24 | $130.8M | — |
| Q1 26 | $317.2M | $653.9M | ||
| Q4 25 | $317.5M | $693.1M | ||
| Q3 25 | $309.2M | $727.2M | ||
| Q2 25 | $298.4M | $757.8M | ||
| Q1 25 | $285.8M | $798.5M | ||
| Q4 24 | $247.7M | $778.3M | ||
| Q3 24 | $241.3M | $749.6M | ||
| Q2 24 | $235.0M | $879.3M |
| Q1 26 | $1.0B | $1.2B | ||
| Q4 25 | $893.8M | $1.3B | ||
| Q3 25 | $891.9M | $1.3B | ||
| Q2 25 | $876.6M | $1.5B | ||
| Q1 25 | $957.1M | $1.6B | ||
| Q4 24 | $759.7M | $1.6B | ||
| Q3 24 | $621.5M | $1.5B | ||
| Q2 24 | $598.1M | $1.6B |
| Q1 26 | 0.02× | — | ||
| Q4 25 | 0.67× | 0.54× | ||
| Q3 25 | 0.71× | 0.52× | ||
| Q2 25 | 0.80× | 0.77× | ||
| Q1 25 | 1.19× | 0.73× | ||
| Q4 24 | 0.88× | 0.75× | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.56× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CECO
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
